Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

被引：3
|
作者：
Moreno, V. [1 ]
Brana, I. [2 ]
Sepulveda Sanchez, J. M. [3 ]
Vieito Villar, M. [4 ]
Hernandez Guerrero, T. [1 ]
Doger, B. [1 ]
Saavedra, O. [2 ]
Pinto, A. [5 ]
Carlo Stella, C. [6 ]
Italiano, A. [7 ]
Michot, J-M. [8 ]
Musuraca, G. [9 ]
Sarmiento, R. [10 ]
De Alvaro, J. [10 ]
Zuraek, M. [11 ]
Sanchez-Perez, T. [10 ]
Aronchik, I. [11 ]
Filvaroff, E. [11 ]
Hanna, B. [11 ]
Nikolova, Z. [10 ]
机构：
[1] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[2] Hosp Univ Vall dHebron, Barcelona, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Hosp Univ Vall Hebron, Barcelona, La Coruna, Spain
[5] Ist Nazl Tumori IRCSS Fdn Pascale, Naples, Italy
[6] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Milan, Italy
[7] Ctr Reg Lutte Canc Bordeaux & Sud Ouest, Inst Bergonie, Bordeaux, France
[8] Inst Gustave Roussy, Dept Hematol, Villejuif, France
[9] Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[10] Celgene, Summit, NJ USA
[11] Bristol Myers Squibb, Summit, NJ USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.01.025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16O
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [41] A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
    Bartlett, NL
    Gribben, JC
    Boccia, RV
    Milder, MS
    Aboulafia, DM
    Castro, J
    Flinn, I
    Hayes-Lattin, B
    Kaplan, L
    Lin, T
    Lucas, JB
    Maloney, DG
    McLaughlin, P
    McSweeney, PA
    Mohrbacher, A
    Redfern, C
    Steis, R
    Stephenson, JJ
    Strair, R
    Berenson, RJ
    Frohlich, MW
    BLOOD, 2004, 104 (11) : 244B - 244B
  • [42] A first in human phase I study of the proteasome inhibitor CEP-18770 in patients (pts) with advanced solid tumors, non-Hodgkin's lymphomas (NHL) and multiple myeloma (MM)
    Sessa, C.
    Martinelli, G.
    Hess, D.
    Delmonte, A.
    Noberasco, C.
    Sammassimo, S.
    Gallerani, E.
    Marsoni, S.
    Camboni, G.
    de Braud, F.
    EJC SUPPLEMENTS, 2010, 8 (07): : 120 - 120
  • [43] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Kensei Tobinai
    Michinori Ogura
    Dai Maruyama
    Toshiki Uchida
    Naokuni Uike
    Ilseung Choi
    Kenichi Ishizawa
    Kuniaki Itoh
    Kiyoshi Ando
    Masafumi Taniwaki
    Naomi Shimada
    Ken Kobayashi
    International Journal of Hematology, 2010, 92 : 563 - 570
  • [44] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Tobinai, Kensei
    Ogura, Michinori
    Maruyama, Dai
    Uchida, Toshiki
    Uike, Naokuni
    Choi, Ilseung
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Shimada, Naomi
    Kobayashi, Ken
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (04) : 563 - 570
  • [45] CC-122, a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)
    Michot, Jean-Marie
    Bouabdallah, Reda
    Doorduijn, Jeanette K.
    Vitolo, Umberto
    Kersten, Marie Jose
    Chiappella, Annalisa
    Zinzani, Pier Luigi
    Sarmiento, Rafael
    Mosulen, Silvia
    Mendez, Cristina
    Petrarca, Michael
    Pourdehnad, Michael
    Hege, Kristen
    Li, Li
    Nikolova, Zariana
    Ribrag, Vincent
    BLOOD, 2017, 130
  • [46] Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
    Davids, Matthew S.
    Roberts, Andrew W.
    Seymour, John F.
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Puvvada, Soham
    Kipps, Thomas J.
    Anderson, Mary Ann
    Salem, Ahmed Hamed
    Dunbar, Martin
    Zhu, Ming
    Peale, Franklin
    Ross, Jeremy A.
    Gressick, Lori
    Desai, Monali
    Kim, Su Young
    Verdugo, Maria
    Humerickhouse, Rod A.
    Gordon, Gary B.
    Gerecitano, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08) : 826 - 833
  • [47] Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).
    Carlo-Stella, Carmelo
    Hutchings, Martin
    Offner, Fritz C.
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Balari, Anna Sureda
    Iacoboni, Gloria
    Haioun, Corinne
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Carlile, David
    Piccione, Emily
    Belousov, Anton
    Humphrey, Kathryn
    Dickinson, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.
    Abramson, Jeremy S.
    Palomba, Maria Lia
    Arnason, Jon E.
    Lunning, Matthew Alexander
    Solomon, Scott R.
    Farazi, Thalia
    Garcia, Jacob
    Xie, Benhuai
    Newhall, Kathryn J.
    Dehner, Christine
    Siddiqi, Tanya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study
    Michot, Jean-Marie
    Chavez, Julio C.
    Carpio, Cecilia
    Ferrari, Silvia
    Feldman, Tatyana A.
    Morillo, Daniel
    Kuruvilla, John
    Pinto, Antonio
    Ribrag, Vincent
    Bachy, Emmanuel
    Buchholz, Tonia J.
    Carrancio, Soraya
    Guarinos, Carla
    Wu, Fan
    Li, Shaoyi
    Patah, Poliana
    Pourdehnad, Michael
    Nastoupil, Loretta
    BLOOD, 2021, 138
  • [50] A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
    Blum, Kristie A.
    Christian, Beth
    Flynn, Joseph M.
    Jaglowski, Samantha M.
    Jones, Jeffrey Alan
    Maddocks, Kami
    Byrd, John C.
    BLOOD, 2012, 120 (21)
12345